{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-187641","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2026-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.982247+00:00","generated_at":"2026-05-15T03:05:44.978735+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Janux reclassifies director Eric Dobmeier from Class III to Class II to rebalance board classes","bullets":["On April 28, 2026, Eric Dobmeier resigned as Class III director and immediately reappointed as Class II director.","Change effective to achieve more equal balance among the three director classes on the Board.","Dobmeier's service deemed uninterrupted for vesting, equity awards, and compensation purposes.","Dobmeier continues on the Compensation Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-187641","json":"https://secwatch.observer/filing/0001193125-26-187641.json","markdown":"https://secwatch.observer/filing/0001193125-26-187641.md","text":"https://secwatch.observer/filing/0001193125-26-187641.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000119312526187641/0001193125-26-187641-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000119312526187641/janx-20260428.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:05:44.978735+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}